FlandersBio on Twitter

Follow us on Twitter

Archive for August 2015 - News

Archive for August 2015 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Officiële inhuldiging nieuwe bedrijfsgebouwen van Anacura in Evergem


Zondag 30 augustus is een belangrijke mijlpaal in de geschiedenis van Anacura, een onderneming uit de Gentse regio met maar liefst 220 medewerkers, die gespecialiseerde diensten aanbiedt aan artsen, onderzoekers en (bio)farmaceutische bedrijven in België en daarbuiten. Aan de Noorwegenstraat 4 te Evergem werden immers de nieuwe laboratoria officieel ingehuldigd. Het gaat om een investering van 18 miljoen euro. De inhuldiging gebeurde in aanwezigheid van Prof. dr. Luc Van den hove, Voorzitter en CEO van imec en van Prof. dr. Leo Neels, voorzitter van de Advisory Board van het Vlerick Healthcare Management Centre. read more

Celyad announces commercial license agreement for C-Cure® in Greater China


Celyad SA (Euronext Brussels, Euronext Paris and Nasdaq: CYAD), a leader in the discovery and development of engineered cell therapies, today announced that it has entered into a new collaboration and distribution agreement with its Hong-Kong based partner, Medisun International Limited (“Medisun”). This license agreement confirms Celyad’s intention to expand the global footprint of its lead cardiac disease cell therapy candidate for the treatment of ischemic heart failure, C-Cure®. read more

ThromboGenics Business Update H1 2015


ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for treatment of vitreo-retinal disorders, today issues a business and financial update for the six months ending 30 June, 2015. read more



Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced its business update and results for the six-month period ending 30 June 2015, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adopted by the European Union. read more



arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided a business update and announced its financial results for the first half of 2015 (six-month period ended June 30, 2015). read more

Various avenues to counteract TNF - crucial to tackling acute inflammation


​The cytokine TNF was discovered exactly 40 years ago. This protein plays and important role in acute inflammation and in a number of auto-immune conditions. TNF needs to pass on a signal in order to execute its role. This can be achieved by binding to a receptor. We know of two different receptors that TNF can bind to, namely TNFR1 and TNFR2. read more

Celyad reports First Half 2015 financial results and operational progress


Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2015 prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report (regulated information) is available on our website in the Investors section. The Half Year 2015 consolidated financial statements were subject to a limited review by the company’s statutory auditors. read more

ESPERITE N.V. (ESP) publishes 2015 half-year results, total revenue increases over same period last year


Esperite NV (Euronext: ESP, "Esperite" or "the Group") has published its financial results (unaudited) for the period of six months ended June 30, 2015 showing an increase in total revenue compared to the same period last year. Esperite has built a successful constellation of companies In less than a year and created its own identity. Esperite's vision and strategy have been validated, the Group's focus has shifted now to implementation and growth. read more

TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial


TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that its lead compound Cx601 met the primary endpoint in the Phase III ADMIRE-CD trial in Crohn's disease patients with complex perianal fistulas. Cx601 is a suspension of allogeneic expanded adipose-derived stem cells (eASC) injected intra-lesionally. A single injection of Cx601 was statistically superior to placebo in achieving combined remission at week 24, in patients with inadequate response to previous therapies, including anti-TNFs. The study results confirm the favourable safety and tolerability profile of Cx601. read more

New insights in pathological mechanism that causes dysfunctional synapses


Genetic analysis of human patients has shown that mutations in genes involved in synaptic communication can drive neuropsychiatric and neurological diseases such as autism spectrum disorder and Alzheimer’s disease. Through a global analysis of the synaptic machinery Jeffrey Savas (Northwestern University Feinberg School of Medicine) and Joris de Wit (VIB/KU Leuven) together with their colleagues revealed for the first time a new pathway that governs the proper sorting of many essential synaptic proteins in neurons. Disruption of this sorting pathway in neuropsychiatric and neurological diseases severely hampers the efficient communication between neurons. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top